RECIST was developed in 2000 by the National Cancer Institute, European Organization for Research and Treatment of Cancer, and National Cancer Institute of Canada, with revision to RECIST 1.1 in 2009 ...

Tissue-engineered and chip-based models are changing how scientists study early cancer, leading to more accurate and humane ...

Different types of hormonal contraceptives may carry distinct risk of developing breast cancer, serving women make well-considered choices.

The FDA has designated Conexxence and Bomyntra as interchangeable biosimilars to the reference products Prolia and Xgeva, ...

The FDA has designated Stoboclo and Osenvelt as interchangeable biosimilars to the reference products Prolia and Xgeva, respectively.

Lutetium Lu 177 vipivotide tetraxetan combined with ARPI and ADT improved rPFS in PSMA-positive mHSPC patients compared to ARPI and ADT alone. Lutetium Lu 177 vipivotide tetraxetan significantly ...

Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar Objective responses and promising anti-tumor activity observed in ...

Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company aiming to develop innovative therapies and to improve patient quality of life, today announced the successful completion of ...

In August 2025, HistoSonics announced that it was being acquired in a pioneering transaction by a group of some of the wealthiest families and sovereign wealth funds in the world in a transaction ...

EQS-News: Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma ...

A European study has demonstrated a sustained long-term reduction in prostate cancer mortality through prostate-specific ...

Osteoporosis is commonly seen as a women's disease, but men face even deadlier consequences from bone fractures.